Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes - Wikidata - awgldk - TriplyDB

Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes

Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes

http://www.wikidata.org/entity/Q28072339

about

Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes

http://www.wikidata.org/entity/Q28072339

description

2016 nî lūn-bûn

@nan

2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Canagliflozin: Efficacy and Sa ...... emic Agents in Type 2 Diabetes

@ast

Canagliflozin: Efficacy and Sa ...... emic Agents in Type 2 Diabetes

@en

Canagliflozin: Efficacy and Sa ...... emic Agents in Type 2 Diabetes

@nl

type

label

Canagliflozin: Efficacy and Sa ...... emic Agents in Type 2 Diabetes

@ast

Canagliflozin: Efficacy and Sa ...... emic Agents in Type 2 Diabetes

@en

Canagliflozin: Efficacy and Sa ...... emic Agents in Type 2 Diabetes

@nl

prefLabel

Canagliflozin: Efficacy and Sa ...... emic Agents in Type 2 Diabetes

@ast

Canagliflozin: Efficacy and Sa ...... emic Agents in Type 2 Diabetes

@en

Canagliflozin: Efficacy and Sa ...... emic Agents in Type 2 Diabetes

@nl

P1433

Q28072339-D5E5579C-F62D-45FB-96C0-2072A275494B

P1476

Q28072339-5E8C9D42-4F0E-4F44-92FE-B98DC4F39B1A

P2093

Q28072339-460DEB49-8C55-46D4-82BA-7F637AA9B0B0

Q28072339-6001CABC-B912-4A49-AB4D-6B7DAFAC1C7B

Q28072339-CEBC0D24-20AB-4CAA-927F-A4D516FF96A7

Q28072339-FC6D9F31-35AA-48F6-8EB8-823266C41797

Q28072339-FD604934-AC10-4F8A-8ABB-9077302CFF91

P2860

Q28072339-03008FC5-CFD7-4B1B-8C0B-55F2C9285C29

Q28072339-08A9EBE0-76AD-4E5D-B71D-3272462AEB29

Q28072339-0FFAA286-73D3-4052-A6A4-2E0DD714DC35

Q28072339-14C6BF58-8C24-4888-BF74-E624A1E1BFD8

Q28072339-2AC4161F-5AC6-44F0-AC3B-E620DB0C7092

Q28072339-3664BA2D-03B2-4924-AD6E-B4E2056BDD6A

Q28072339-37275313-E11C-432B-B2FC-CB2FEDB664C4

Q28072339-3F232A03-ED44-4ED0-8BB9-891076F49009

Q28072339-45D5A385-CBAA-4A5C-BBC5-18E35A89BAE9

Q28072339-46A74345-BE03-4D06-8554-5484DACC937E

P2888

Q28072339-441CEDDE-4150-4B11-9AB1-D797F46EE723

P304

Q28072339-CD225C4A-ED70-4B50-938E-51C183CBB018

P31

Q28072339-F839BE04-D245-4F74-94AD-875921B7C73C

P3181

Q28072339-24F5B029-59CD-4582-ACA3-A7A017FCB4A5

P356

Q28072339-C97EC83F-D705-44F8-A1A2-74964333D1D5

P407

Q28072339-1BCDC7B4-CBD9-4726-A65B-BF54EFDE8CE9

P433

Q28072339-DE23783B-12A2-4877-8558-C0DD74408FD6

P478

Q28072339-B82B0023-DC93-4F35-9A5C-DF3536C172FA

P577

Q28072339-CE641304-E7BD-428E-A679-CB951BC7FFDC

P6179

Q28072339-B7B2E4F3-DE8A-4B88-98A3-437FC4A1BD72

P698

Q28072339-AA01FF62-78A5-47FA-B31F-B3085372545D

P921

Q28072339-6F9D23E8-F284-43CA-B4B8-5E99C34F438B

Q28072339-F7295224-76F3-4501-AE7B-7CB946CE20D2

P932

Q28072339-86886511-8E9C-4468-8324-6B82854E46B1

P3181

P356

S13300-016-0201-Z

P1433

Diabetes Therapy

P1476

Canagliflozin: Efficacy and Sa ...... emic Agents in Type 2 Diabetes

@en

P2093

Dainius Balis

http://www.w3.org/2001/XMLSchema#string

Gary Meininger

http://www.w3.org/2001/XMLSchema#string

George Capuano

http://www.w3.org/2001/XMLSchema#string

John Xie

http://www.w3.org/2001/XMLSchema#string

Rong Qiu

http://www.w3.org/2001/XMLSchema#string

P2860

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

The target of metformin in type 2 diabetes

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Association of Cardiometabolic Multimorbidity With Mortality

10-year follow-up of intensive glucose control in type 2 diabetes

SGLT2 inhibition--a novel strategy for diabetes treatment.

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

P2888

s13300-016-0201-z

P304

659-678

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3020485

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S13300-016-0201-Z

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1034619875

http://www.w3.org/2001/XMLSchema#string

P698

27734320

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

5118239

http://www.w3.org/2001/XMLSchema#string